Biotronik looks to get into the TAVI game
Biotronik touts 1st-in-human data for its entry into the transcatheter aortic valve implant market, saying the device passed its 30-day safety endpoint.
Biotronik today said its entry into a hot replacement heart valve market passed the safety endpoint of a 1st-in-human trial.
The German medical device giant said the Biovalve trial of its transcatheter aortic valve implant established the device's early safety at 30 days.
BiotronikNews Well, Clinical Trials, Replacement Heart Valves, TAVIread more
Source: Mass Device - Category: Medical Equipment Authors: Brad Perriello Source Type: news
More News: Cardiology | Clinical Trials | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Medical Devices